Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 15, 2011 Selena Maranjian	Make Money in Biotech the Easy Way There's no need to guess which biotech company will perform best with the SPDR S&P Biotech ETF.
The Motley Fool April 4, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry.
The Motley Fool October 26, 2011 Selena Maranjian	Make Money in Promising Biotech Stocks the Easy Way If you expect the biotech industry to thrive as scientists develop more drugs to treat our aging population, the iShares Nasdaq Biotechnology ETF could be for you.
The Motley Fool May 5, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry.
The Motley Fool November 22, 2011 Selena Maranjian	Make Money in Global Health-Care Stocks the Easy Way If you expect the global health-care industry to thrive as our planet's population grows and ages, the iShares S&P Global Health Care ETF could save you a lot of trouble.
The Motley Fool July 30, 2007 Amanda B. Kish	The Key to ETF Success As firms such as Vanguard and Barclays continue to duke it out for dominance in the ETF arena, costs will likely continue to fall across the board. That should be a good thing -- for both investors and the ETF market in general.
The Motley Fool April 18, 2008 Selena Maranjian	High-Revenue ETFs Focus on what you'll earn, not what the fund company will.
The Motley Fool December 18, 2006 Buz Livingston	Naughty: The ETF Industry Too much of a good thing is not always good. Close to 400 ETFs are available, and more are in the pipeline for 2007. The industry should follow Vanguard's lead and offer a limited number of low-cost ETFs.
The Motley Fool March 25, 2011 Dan Caplinger	This China Play Is a Better Bet Different Chinese ETFs have different levels of risk. Pick the one that's right for you.
The Motley Fool December 1, 2008 Zoe Van Schyndel	A Better Way to Invest in Biotech? Structured as a trust, the Biotech HOLDR holds common stock of companies in the biotechnology industry. But don't confuse HOLDRs with exchange-traded funds.
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.
The Motley Fool November 16, 2006 Jim Fink	The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007.
The Motley Fool January 19, 2010 Amanda B. Kish	The Hottest Trillion-Dollar Investment Read these tips before jumping into the popular world of exchange-traded funds.
Financial Planning November 1, 2007 Donald Jay Korn	Thick or Thin? A few ETFs account for most of the trading volume in this popular asset class. The rest merit close scrutiny -- for costs, liquidity and diversification.
The Motley Fool August 29, 2007 Amanda B. Kish	The Best Small-Cap ETFs These exchange-traded funds win the best-in-class award. Let's take a closer look at the iShares Russell 2000 Index ETF, the Vanguard Small-Cap ETF, the iShares Morningstar Small Core ETF, the iShares S&P 600 Value ETF, and the Vanguard Small-Cap Growth ETF.
The Motley Fool January 12, 2004 Dave Marino-Nachison	All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials.
Investment Advisor April 2010 Vaughan Scully	The ETF Advisor: Prospects for Healthcare ETFs Better Than Those for Reform There are about two dozen exchange traded funds that offer a wide variety of exposures to the healthcare sector, including broad-based, global, and leveraged ETFs, as well as those targeting individual industries.
The Motley Fool October 4, 2011 Selena Maranjian	Small ETFs Carry Big Dangers Some ETFs, despite their low fees, can cost you a lot.
The Motley Fool August 16, 2010 Dan Caplinger	This Tip Will Make You a Smarter ETF Investor Here are some tips to use and traps to avoid.
Registered Rep. April 4, 2012 David Trainer	The Intelligent Investor: How to Find the Best ETFs There are a few easy screens to cull out ETFs that should be avoided and there are lots of free services for determining which ETFs are right for you.
The Motley Fool June 15, 2011 Dan Caplinger	5 ETFs You Need to Get Rich These five ETFs give you nearly everything you need in order to build wealth.
The Motley Fool February 3, 2010 Dan Caplinger	The Answer You've Been Waiting For Back in November, Charles Schwab announced that it would introduce exchange-traded funds of its own. Fidelity answers Schwab with an even better deal for investors.
The Motley Fool April 9, 2010 Brian Orelli	Double Your Biotech Returns! Really! Taking a closer look at leveraged biotech ETFs.
The Motley Fool May 6, 2010 Dan Caplinger	These ETF Traps Could Burn You Some exchange-traded funds aren't as diversified as you think.
The Motley Fool September 1, 2010 Amanda B. Kish	How to Win at the ETF Game Make cost one of your primary objectives when shopping for exchange-traded funds or other investments.
The Motley Fool January 31, 2007 Zoe Van Schyndel	Health Care, Thinly Sliced Five new health-care-focused ETFs, the HealthShares family, provide increasingly specific ways to invest in health care.
The Motley Fool September 15, 2010 Dan Caplinger	6 ETFs That Won't Rip You Off Don't pay more than you have to for ETFs.
The Motley Fool November 15, 2011 Selena Maranjian	Make Money in Biotech and Genome Stocks the Easy Way If you expect biotech firms and companies specializing in genomics to thrive as advances in health care and medicine continue, the PowerShares Dynamic Biotech & Genome ETF could save you a lot of trouble.
The Motley Fool September 12, 2007 Amanda B. Kish	ETFs Spread Themselves Thin Some newer small-niche ETFs are facing low trading volume and wider spreads, which can cut into investment returns. Investors should take note of this.
The Motley Fool October 5, 2011 Dan Caplinger	A Leader That Could Make You Rich iShares lead the industry with hundreds of ETF offerings.
The Motley Fool October 25, 2011 Dan Caplinger	4 ETFs You Can Count On Hundreds of ETFs could go away soon, but these will continue on.
The Motley Fool December 15, 2011 Dan Caplinger	What These Top ETF Picks Predict for 2012 ETF trends can tell you a lot about investing generally.
The Motley Fool June 18, 2009 Daniel Harrison	Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains.
The Motley Fool August 12, 2010 Amanda B. Kish	3 New ETFs Worth Buying Here are three new ETFs worth a second look.
The Motley Fool April 5, 2010 Brian Orelli	1 Month to Go! Is Dendreon a Buy? Only if you understand the risks.
The Motley Fool September 8, 2008 Selena Maranjian	ETFs on the Rise Will exchange-traded funds put mutual funds out of business?
The Motley Fool August 17, 2010 Dan Caplinger	This Trap Could Cost You Thousands ETFs can be useful, but you may not be as diversified as you think.
Financial Advisor July 2012 Tom Lydon	In The ETF Price War, Investors Win Advisors have many options for helping clients save on fees.
The Motley Fool September 28, 2010 Brian Orelli	It's Up! It's Down! It's Dendreon! The joys of biotech.
The Motley Fool November 16, 2011 Selena Maranjian	Make Money in Growing Timber and Paper Companies the Easy Way If you expect companies focusing on timber, paper, and packaging to thrive once the housing market starts to pick up, the iShares S&P Global Timber & Forestry ETF could save you a lot of trouble.
The Motley Fool December 28, 2011 Dan Caplinger	This Was the Preferred Investment of 2011 Let's look back at how the year went for this ETF. Given just how badly bank stocks did this year, you would think that an exchange-traded fund that focuses on bank-issued securities would have suffered huge losses.
The Motley Fool May 18, 2009 Dan Caplinger	Don't Let Dying ETFs Snare You In a sign of the times, some ETFs have decided to pull the plug after failing to attract a big following from investors.
Registered Rep. January 2, 2014 Stan Luxenberg	The Case for Mutual Funds Proponents of ETFs often argue that traditional mutual funds are obsolete -- black-and-white TVs in an age of streaming video. But the advantages of the ETF structure are limited, and they are eroded by the costs of trading.
Financial Planning January 1, 2013 Allan S. Roth	ETF Fees Drop Amid Competitive Battle In a remarkably short period, the playing field for the lowest-cost ETFs has changed dramatically.
Financial Advisor September 2004 Marla Brill	A Biotechnology Fund On Sedatives Eaton Vance's Worldwide Health Sciences Fund manager Sam Isaly takes some nail biting out of biotech investing.
The Motley Fool May 19, 2010 Dan Caplinger	How to Win With Fidelity's Free iShares ETFs Rather than going the same route as Schwab and Vanguard -- by offering in-house funds -- Fidelity has decided to make a partnership deal with ETF provider iShares.
The Motley Fool February 10, 2011 Dan Caplinger	How to Find the Perfect ETF A new method rates ETFs on how well they get the job done.
The Motley Fool May 5, 2010 Dan Caplinger	Vanguard Enters the Broker Wars The fund giant undercuts the competition and offers free ETFs.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
Entrepreneur August 2007 Scott Bernard Nelson	Exchange-Traded vs. Index Funds Tried-and-true index funds still rank highest, but exchange-traded funds can add spice to a well-rounded portfolio.